RINRI THERAPEUTICS LIMITED

Active Sheffield

Research and experimental development on biotechnology

14 employees website.com
Life sciences and medical technology Research and experimental development on biotechnology
R

RINRI THERAPEUTICS LIMITED

Research and experimental development on biotechnology

Founded 15 Nov 2018 Active Sheffield, United Kingdom 14 employees website.com
Life sciences and medical technology Research and experimental development on biotechnology
Accounts Submitted 8 Jul 2025 Next due 30 Sept 2026 4 months remaining
Confirmation Submitted 5 Dec 2025 Next due 28 Nov 2026 6 months remaining
Net assets £-16M £5M 2024 year on year
Total assets £5M £249K 2024 year on year
Total Liabilities £21M £5M 2024 year on year
Charges None No charges registered

Contact & Details

Contact

Registered Address

The Innovation Centre 217 Portobello Sheffield South Yorkshire S1 4DP

Telephone

0800 000 0000

Email

info@example.com

Website

www.example.com

Full company profile for RINRI THERAPEUTICS LIMITED (11680455), an active life sciences and medical technology company based in Sheffield, United Kingdom. Incorporated 15 Nov 2018. Research and experimental development on biotechnology. View financials, directors, shareholders, and filings.

Business Summary

This company specializes in providing innovative solutions and services across multiple sectors.

Products & Services

consulting software analytics integration

Reports

Credit Report

In-depth credit score, financial analysis, risk assessment and company intelligence.

Financials

Financials

Period 1 Jan → 31 Dec 2024
Type Total Exemption Full
Next accounts 31 December 2025
Due by 30 September 2026 9 months

Net Assets, Total Assets & Total Liabilities (2019–2024)

Cash in Bank

£3.70M

Decreased by £1.20M (-25%)

Net Assets

-£15.92M

Decreased by £5.25M (-49%)

Total Liabilities

£21.17M

Increased by £5.00M (+31%)

Turnover

N/A

Employees

14

Increased by 1 (+8%)

Debt Ratio

403%

Increased by 109 (+37%)

Financial History

Revenue, profit, EBITDA and key financial figures

2024
Dec Year End
2023
Dec Year End
P&L
Revenue
£142.3M
£128.7M
Gross Profit
£48.2M
£43.1M
Operating Profit
£22.4M
£19.8M
Net Profit
£18.1M
£15.9M
EBITDA
£31.5M
£28.2M
Assets
Cash
£24.7M
£21.3M
Total Assets
£89.4M
£82.1M
Liabilities
Total Liabilities
£45.2M
£41.8M
Key Metrics
Employees
1,247
1,156
Latest Revenue
£142.3M
Latest EBITDA
£31.5M
Cash Position
£24.7M

Funding

Fundraising & Grants

Funding Rounds 2
Grants 3

Investors (4)

Investor NameInvestor SinceParticipating Rounds
Investor 1May 2019Seed, Series A
Investor 2May 2019Seed, Series A
Investor 3May 2019Seed, Series A

Share Capital

Share Capital

Share allotments and capital structure

2 Allotments 4,042 Shares £3k Total
Date FromShare ClassShares AllottedAmount RaisedPrice/Share
6 Feb 20241,555£1k£0.75
24 Jan 20242,487£2k£0.75

Officers

Officers

1 active 2 resigned
Status
David John HipkissDirectorBritishUnited Kingdom558 Apr 2024Active

Shareholders

Shareholders (8)

Ucb Ventures Sa
24.6%
69,900
Boehringer Ingelheim Venture Fund Gmbh
24.6%
69,900

Persons with Significant Control

Persons with Significant Control (1)

1 Active 1 Ceased

Uk Ff Nominees Limited

Unknown

Active
Notified 4 Mar 2026
Nature of Control
  • Ownership Of Shares 25 To 50 Percent
  • Voting Rights 25 To 50 Percent

Professor Carlos Marcelo Nicolas Rivolta

Ceased 22 Feb 2019

Ceased

Group Structure

Group Structure

RINRI THERAPEUTICS LIMITED Current Company

Charges

Charges

No charges registered

Properties

Properties

0 total

No related properties

Documents

Company Filings

DateCategoryDescriptionDocument
9 Apr 2026Persons With Significant ControlUk Ff Nominees Limited notified as a person with significant control
8 Apr 2026ResolutionResolutions
8 Apr 2026Persons With Significant ControlWithdrawal Of A Person With Significant Control Statement
8 Apr 2026CapitalCapital Name Of Class Of Shares
8 Apr 2026IncorporationMemorandum Articles
9 Apr 2026 Persons With Significant Control

Uk Ff Nominees Limited notified as a person with significant control

8 Apr 2026 Resolution

Resolutions

8 Apr 2026 Persons With Significant Control

Withdrawal Of A Person With Significant Control Statement

8 Apr 2026 Capital

Capital Name Of Class Of Shares

8 Apr 2026 Incorporation

Memorandum Articles

Recent Activity

Latest Activity

Uk Ff Nominees Limited notified as a person with significant control

3 weeks ago on 9 Apr 2026

Resolutions

4 weeks ago on 8 Apr 2026

Withdrawal Of A Person With Significant Control Statement

4 weeks ago on 8 Apr 2026

Capital Name Of Class Of Shares

4 weeks ago on 8 Apr 2026

Memorandum Articles

4 weeks ago on 8 Apr 2026